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1713culprit/target lesions could be TCFAs. Therefore, it
would be of great help if the authors could provide
the number of the culprit/target lesions in each
group.
In addition, the authors previously reported 58
TCFAs and 19 ruptured plaques in 184 nonculprit le-
sions in 82 patients with acute coronary syndrome (2).
Because the ruptured plaques resulted from TCFAs, I
would appreciate it if the authors could provide the
number of the ruptured plaques in each group,
although angiographic stenosis could change to some
degree after rupture. These data can help us to
completely understand the relationship between
vulnerable plaque and angiographic stenosis.FIGURE 1 Incidence of PPMI in the Presence of Factors Associated With an
Increased Risk of Ischemic Myocardial Injury During PCI
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An Independent Link Between Diabetes
Mellitus, Impaired On-Clopidogrel Platelet
Inhibition, and Major Adverse Cardiac Events
After Percutaneous Coronary Intervention0
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Subjects with baseline ﬁbrinogen level $345 mg/dl had a higher incidence of both CK-MB–
deﬁned PPMI (*controlled for platelet reactivity and inﬂammatory markers) and troponin
I/T–deﬁned PPMI (†controlled for age, platelet count, platelet reactivity, and inﬂammatory
markers) supported by multiple variable testing. Subjects with an elevated baseline
ﬁbrinogen level in the absence of systemic inﬂammation (CRP #0.5 mg/dl) had an even
higher incidence of CK-MB–deﬁned PPMI based on multiple variable interaction testing
(‡controlled for ﬁbrinogen and CRP), but a higher incidence of troponin I/T–deﬁned
PPMI was only supported by univariate analysis (§). *†‡Multiple variable regression
p value <0.05; §univariate p value <0.05. CK-MB ¼ creatine kinase-myocardial band;
CRP ¼ C-reactive protein; PPMI ¼ periprocedural myocardial infarction; PRU ¼ P2Y12
reactivity unit. Reproduced with permission from Ang et al. (4).We read with great interest the recent paper and
editorial written by Angiolillo et al. (1) and Price (2)
in the Journal regarding diminished platelet inhibi-
tion (PI) response to clopidogrel in diabetic patients
attributable to impaired metabolism of the clopi-
dogrel prodrug to its active metabolite in subjects
with stable coronary artery disease (CAD). As cited by
the authors, we previously identiﬁed an elevated
serum ﬁbrinogen level in diabetic patients undergo-
ing PCI to be associated with impaired on-clopidogrel
PI (3). Before interaction testing, decreased PI was
observed in the presence of diabetes mellitus (DM)
(34.4  23.0 vs. 47.4  28.7%; p ¼ 0.021) and
ﬁbrinogen $375 mg/dl (31.9  23.0 vs. 44.8  26.8%;p ¼ 0.047). After testing for interactions, elevated
ﬁbrinogen together with DM (p ¼ 0.026), indepen-
dent of either DM (p ¼ 0.457) or elevated ﬁbrinogen
(p ¼ 0.600) alone, remained signiﬁcantly associated
with lower PI.
After this observation, the following remained
unclear: 1) whether elevated ﬁbrinogen in diabetic
patients is simply a marker of greater systemic
inﬂammation or actively facilitates increased platelet
cross-linking as measured by in vitro platelet aggre-
gation testing, and 2) with an elevated ﬁbrinogen
level, is it impaired on-treatment PI or DM most
closely associated with the occurrence of major
adverse cardiac events (MACE) after PCI? Subse-
quently, we reported our ﬁndings in the Journal
that an elevated ﬁbrinogen level, independent of
platelet reactivity or DM, is associated with myo-
cardial infarction within 24 h after PCI (odds ratios:
ﬁbrinogen $345 mg/dl 4.75 [95% conﬁdence interval:
1.2 to 18.5]), whereas PI <30% or the presence of
DM is not associated (4) (Figure 1). In the subset of
subjects without systemic inﬂammation (C-reactive
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1714protein <0.5 mg/dl), the occurrence of MI remained
greater among those with an elevated ﬁbrinogen
level (deﬁned as creatine kinase-myocardial band >3
times upper limit of normal: 16.2 vs. 1.0%; p ¼ 0.002;
deﬁned as troponin I/T >3 times upper limit of
normal: 27.8% vs. 9.2%, p ¼ 0.007). Longer term
follow-up reveals that the association between
elevated ﬁbrinogen level and occurrence of 6-month
MACE after PCI persists independently of on-
clopidogrel PI or DM (5).
Identifying impaired metabolism of the clopidogrel
prodrug provides an important mechanistic insight
for reduced PI in diabetic patients. Further increased
on-clopidogrel platelet reactivity correlates with dia-
betes and higher coronary atherosclerotic disease
burden and calciﬁcation as detected by angiography
or intravascular ultrasound (IVUS) imaging. However,
the relationship between coronary artery calciﬁcation
and body morphology is more complex, with an in-
verse association reported based on a comprehensive
3-dimensional IVUS-based evaluation. This is of
relevance in diabetic patients who usually have a
higher body mass index. Nevertheless, elevated
serum ﬁbrinogen might be an important mechanistic
and clinical link between the presence of impaired
on-clopidogrel PI, DM with or without systemic
inﬂammation, and the occurrence of MACE after PCI,
especially in patients with a high atherosclerotic
disease burden and greater substrate for athero-
thrombotic events. Although MACE in patients with
CAD are attributable to multiple factors, additional
studies are warranted to evaluate the role of ﬁbrin-
ogen as an independent biomarker, in the absence of
systemic inﬂammation, of long-term outcomes in
patients treated with dual-antiplatelet therapy.Lawrence Ang, MD
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An Independent Link Between Diabetes Mellitus, Impaired
On-Clopidogrel Platelet Inhibition, and Major Adverse
Cardiac Events After Percutaneous Coronary InterventionWe greatly appreciate the positive comments by
Drs. Ang and Mahmud regarding our recent paper,
which providedmechanistic insights into the impaired
response to clopidogrel in patients with diabetes mel-
litus (DM) (1). Drs. Ang andMahmud correctly point out
another key mechanism that may be associated with
adverse outcomes in patients with DM undergoing
percutaneous coronary intervention, which is that
associated with elevated serum ﬁbrinogen levels (2,3).
Indeed, the investigators have pioneered this ﬁeld of
research that has provided important insights into the
complex pathophysiological mechanisms involved
in atherothrombotic complications in DM patients.
Accordingly, in our paper, we acknowledge that mul-
tiple factors, including ﬁbrinogen, are involved in
adverse outcomes in DM patients (1,4). However,
deﬁning the relative contribution of each of these
factors, which may also be patient speciﬁc, remains a
challenge and indeed beyond the scope of mechanistic
studies designed to address a speciﬁc hypothesis. The
goal of our investigation was to delineate mechanisms
involved in the impaired clopidogrel response by
integrating quite complex in vitro and ex vivo
experiments in the setting of a prospective study
including pharmacokinetic and pharmacodynamic
assessments (1). Preliminary work by our group and by
others have set the foundation for the study design
that we used (4,5). We showed that the impaired
platelet inhibitor effects of clopidogrel in DM patients
is largely attributable to attenuation of clopidogrel’s
pharmacokinetic proﬁle, characterized by lower
plasma levels of its active metabolite and only
modestly attributed to altered functional status of the
P2Y12 signaling pathway (1). Indeed, this mechanistic
study is simply 1 piece of a puzzle of an overall very
complex disease status in DM patients. Although other
factors were not addressed, this does not exclude their
important role. Moreover, the observation that not all
DM patients with impaired response to clopidogrel or
